Martina Damo1,2, D Scott Wilson1,2, Elyse A Watkins1, Jeffrey A Hubbell1,2. 1. Institute for Molecular Engineering, University of Chicago, Chicago, IL, United States. 2. Institute for Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Abstract
Hepatocytes compose up to 80% of the total liver and have been indicated as important players in the induction of immunologic tolerance in this organ. We show that hepatocytes possess the molecular machinery required for the cross-presentation of extracellular antigens. Using a derivative of the model antigen ovalbumin (OVA) covalently modified with a polymer containing multiple N-acetylgalactosamine residues (pGal-OVA) that enhance extracellular antigen uptake by mimicking the glycome of apoptotic debris, we show efficient hepatocyte-dependent induction of cross-tolerance of both adoptively transferred OT-I cells and endogenous OVA-specific CD8+ T lymphocytes, for example inducing tolerance to OVA-expressing skin transplants. Our study confirms that hepatocytes are capable of inducing peripheral tolerogenesis and provides proof of concept that they may be a valuable candidate for in vivo targeted tolerogenic treatments.
Hepatocytes compose up to 80% of the total liver and have been indicated as important players in the induction of immunologic tolerance in this organ. We show that hepatocytes possess the molecular machinery required for the cross-presentation of extracellular antigens. Using a derivative of the model antigen ovalbumin (OVA) covalently modified with a n class="Chemical">polymer containing multiple N-acetylgalactosamine residues (pGal-OVA) that enhance extracellular antigen uptake by mimicking the glycome of apoptotic debris, we show efficient hepatocyte-dependent induction of cross-tolerance of both adoptively transferred OT-I cells and endogenous OVA-specific CD8+ T lymphocytes, for example inducing tolerance to OVA-expressing skin transplants. Our study confirms that hepatocytes are capable of inducing peripheral tolerogenesis and provides proof of concept that they may be a valuable candidate for in vivo targeted tolerogenic treatments.
Authors: Lauren E Holz; Alessandra Warren; David G Le Couteur; David G Bowen; Patrick Bertolino Journal: J Autoimmun Date: 2009-09-09 Impact factor: 7.094
Authors: Mahzad Akbarpour; Kevin S Goudy; Alessio Cantore; Fabio Russo; Francesca Sanvito; Luigi Naldini; Andrea Annoni; Maria Grazia Roncarolo Journal: Sci Transl Med Date: 2015-05-27 Impact factor: 17.956
Authors: Judith Rauen; Christoph Kreer; Arlette Paillard; Suzanne van Duikeren; Willemien E Benckhuijsen; Marcel G Camps; A Rob P M Valentijn; Ferry Ossendorp; Jan W Drijfhout; Ramon Arens; Sven Burgdorf Journal: PLoS One Date: 2014-08-19 Impact factor: 3.240
Authors: Chitavi D Maulloo; Shijie Cao; Elyse A Watkins; Michal M Raczy; Ani S Solanki; Mindy Nguyen; Joseph W Reda; Ha-Na Shim; D Scott Wilson; Melody A Swartz; Jeffrey A Hubbell Journal: Front Immunol Date: 2021-09-24 Impact factor: 7.561